Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2121

Sort by

Sort Order Select

Journal Articles

TLR8 gain of function: a tall surprise

Bertrand Boisson, Jean-Laurent Casanova

Blood (2021) 137 (18): 2420–2422.

https://doi.org/10.1182/blood.2020010463

Published: 2021

Journal Articles

Common variable immune deficiency: case studies

Charlotte Cunningham-Rundles

Blood (2019) 134 (21): 1787–1795.

https://doi.org/10.1182/blood.2019002062

Published: 2019

Journal Articles

High Mobility Group A1 Chromatin Regulators Function As Critical Drivers of Leukemogenesis in Preclinical Models of Relapsed, Pediatric B-Cell ALL

Liping Li, MD PhD, Katharina Hayer, Lingling Xian, MD PhD, Li Luo, PhD, Leslie Cope, Andrei Thomas-Tikhonenko, PhD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 3946.

https://doi.org/10.1182/blood-2019-130261

Published: 2019

Journal Articles

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

Alessandra Di Grande, BSc, Sofie Piers, Pieter Van Vlierberghe, PhD, Triona Ni Chonghaile, PhD BSc

Blood (2019) 134 (Supplement_1): 3800.

https://doi.org/10.1182/blood-2019-127970

Published: 2019

Journal Articles

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Allison Barraclough, Edward Yoo, Chan Y. Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, MD, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, MBBS,FRACP,FRCPA, Stephen Opat, Zoe McQuilten, Erica M. Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes

Blood (2019) 134 (Supplement_1): 3986.

https://doi.org/10.1182/blood-2019-129294

Published: 2019

Journal Articles

NUP98-KDM5A Fusion Induces Hematopoietic Cell Proliferation and Alters Myelo-Erythropoietic Differentiation

Jonathan Miller, MD PhD, Ryan Hiltenbrand, MS, Tamara Lamprecht, BS, Aman Seth, MS, Sherif Abdelhamed, PhD, Ilaria Iacobucci, PhD, Charles G. Mullighan, MBBS, MD, Jeffery M. Klco, MD PhD

Blood (2019) 134 (Supplement_1): 3775.

https://doi.org/10.1182/blood-2019-130768

Published: 2019

Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 3961.

https://doi.org/10.1182/blood-2019-132041

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Xiaona You, PhD, Zhi Wen, PhD, Guangyao Kong, Adhithi Rajagopalan, BS, Erik A. Ranheim, MD PhD, Yun Zhou, MS, Mrinal M Patnaik, MDMBBS, Jing Zhang, PhD

Blood (2019) 134 (Supplement_1): 3790.

https://doi.org/10.1182/blood-2019-131347

Published: 2019

Journal Articles

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Junjing Qiao, MD PhD, Dandan Zhao, MD, Le Xuan Truong Nguyen, PhD, Herman Wu, BS, Gang Liu, PhD, Shanshan Suo, MD, Huafeng Wang, Yasmin Elhajmoussa, Chen Liang, MD, David Snyder, MD, Haris Ali, MD, Steven Rosen, MD, Nadia Carlesso, MD, Ling Li, PhD, Ya-Huei Kuo, PhD, Guido Marcucci, MD, Bin Zhang, PhD

Blood (2019) 134 (Supplement_1): 3791.

https://doi.org/10.1182/blood-2019-127616

Published: 2019

Journal Articles

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 3997.

https://doi.org/10.1182/blood-2019-128632

Published: 2019

Journal Articles

Combined Heterozygous Loss of Tet2 and Dnmt3a Along with Expression of Flt3 ITD/WT results in Acute Myeloid Leukemia Which Responds to a Combination of FLT3 Inhibitor, APE1 Inhibitor and Decitabine

Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Raghuveer Singh Mali, PhD, Zhigang Cai, PhD, Ruchi Pandey, PhD, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 3754.

https://doi.org/10.1182/blood-2019-131172

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 4059.

https://doi.org/10.1182/blood-2019-124812

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lauren K. Meyer, Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, Michelle L. Hermiston, MD PhD, Kim E. Nichols, MD

Blood (2019) 134 (Supplement_1): 81.

https://doi.org/10.1182/blood-2019-129112

Published: 2019

Journal Articles

Genetic of Sporadic Hemophagocytic Lymphohistiocytosis

Coralie Bloch, MD PhD, Jean-Philippe Jais, MD PhD, Marine Gil, Marouane Boubaya, PhD, Felipe Suarez, MD PhD, Brigitte Bader-Meunier, MD, Nizar Malhaoui, MD PhD, Alain Fischer, MD PhD, Genevieve de Saint Basile, MD PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 82.

https://doi.org/10.1182/blood-2019-129743

Published: 2019

Journal Articles

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Nathan Eaton, BS, Melissa M. Lee-Sundlov, PhD, Theresa A. Dlugi, PhD, Jon Wieser, BS, Haley E. Ramsey, PhDMSc, Martha Sola-Visner, MD, Karin M. Hoffmeister, MD, Hervé Falet, PhD

Blood (2019) 134 (Supplement_1): 2477.

https://doi.org/10.1182/blood-2019-126820

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)

Hannah Newman, BS, Anthony M. Hunter, MD, Christopher Letson, BS, Amy E. DeZern, MD, Maria E Balasis, William Dominguez-Viqueira, PhD, Alexis Vedder, BS, Traci Kruer, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Gail J. Roboz, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 2984.

https://doi.org/10.1182/blood-2019-128541

Published: 2019

NARROW

TLR8 gain of function: a tall surprise

Common variable immune deficiency: case studies

High Mobility Group A1 Chromatin Regulators Function As Critical Drivers of Leukemogenesis in Preclinical Models of Relapsed, Pediatric B-Cell ALL

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

NUP98-KDM5A Fusion Induces Hematopoietic Cell Proliferation and Alters Myelo-Erythropoietic Differentiation

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Combined Heterozygous Loss of Tet2 and Dnmt3a Along with Expression of Flt3 ITD/WT results in Acute Myeloid Leukemia Which Responds to a Combination of FLT3 Inhibitor, APE1 Inhibitor and Decitabine

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Genetic of Sporadic Hemophagocytic Lymphohistiocytosis

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only